Air-leak syndrome following allo-SCT in adult patients

Report from the Kanto Study Group for Cell Therapy in Japan

R. Sakai, H. Kanamori, C. Nakaseko, F. Yoshiba, K. Fujimaki, T. Sakura, S. Fujisawa, N. Kawai, M. Onoda, T. Matsushima, A. Maruta, H. Sakamaki, Shinichiro Okamoto

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We retrospectively investigated air-leak syndrome (ALS), including pneumothorax and mediastinal/s.c. emphysema, following allogeneic hematopoietic SCT. Eighteen patients (1.2%) developed ALS among 1515 undergoing SCT between 1994 and 2005 at the nine hospitals participating in the Kanto Study Group on Cell Therapy. The median onset of ALS was at 575 days (range: 105-1766) after SCT and 14 patients (77.8%) had experienced late onset noninfectious pulmonary complications (LONIPC) before ALS. Chronic GVHD (cGVHD) was the strongest risk factor for ALS (odds ratio 13.5, P0.013 by multivariate analysis). Repeat SCT, male sex and age 38 years at the time of transplantation were also significant risk factors for ALS. Patients with ALS had a significantly worse survival rate than those without ALS (61.5 vs 14.9% at 3 years; P0.000). The main cause of death was respiratory complications in 8 of the 18 patients. In conclusion, ALS is a rare complication of SCT that is more likely to occur in relatively young male patients with cGVHD and/or LONIPC. It is possible that better understanding and treatment of LONIPC may lead to prevention of ALS.

Original languageEnglish
Pages (from-to)379-384
Number of pages6
JournalBone Marrow Transplantation
Volume46
Issue number3
DOIs
Publication statusPublished - 2011 Mar

Fingerprint

Group Psychotherapy
Cell- and Tissue-Based Therapy
Japan
Air
Lung
Mediastinal Emphysema
Pneumothorax
Cause of Death
Multivariate Analysis
Survival Rate
Transplantation
Odds Ratio

Keywords

  • air-leak syndrome
  • allo-SCT
  • chronic GVHD
  • late onset noninfectious pulmonary complications

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Air-leak syndrome following allo-SCT in adult patients : Report from the Kanto Study Group for Cell Therapy in Japan. / Sakai, R.; Kanamori, H.; Nakaseko, C.; Yoshiba, F.; Fujimaki, K.; Sakura, T.; Fujisawa, S.; Kawai, N.; Onoda, M.; Matsushima, T.; Maruta, A.; Sakamaki, H.; Okamoto, Shinichiro.

In: Bone Marrow Transplantation, Vol. 46, No. 3, 03.2011, p. 379-384.

Research output: Contribution to journalArticle

Sakai, R, Kanamori, H, Nakaseko, C, Yoshiba, F, Fujimaki, K, Sakura, T, Fujisawa, S, Kawai, N, Onoda, M, Matsushima, T, Maruta, A, Sakamaki, H & Okamoto, S 2011, 'Air-leak syndrome following allo-SCT in adult patients: Report from the Kanto Study Group for Cell Therapy in Japan', Bone Marrow Transplantation, vol. 46, no. 3, pp. 379-384. https://doi.org/10.1038/bmt.2010.129
Sakai, R. ; Kanamori, H. ; Nakaseko, C. ; Yoshiba, F. ; Fujimaki, K. ; Sakura, T. ; Fujisawa, S. ; Kawai, N. ; Onoda, M. ; Matsushima, T. ; Maruta, A. ; Sakamaki, H. ; Okamoto, Shinichiro. / Air-leak syndrome following allo-SCT in adult patients : Report from the Kanto Study Group for Cell Therapy in Japan. In: Bone Marrow Transplantation. 2011 ; Vol. 46, No. 3. pp. 379-384.
@article{2f1f30ae2e0b4ce79caf13610accafc6,
title = "Air-leak syndrome following allo-SCT in adult patients: Report from the Kanto Study Group for Cell Therapy in Japan",
abstract = "We retrospectively investigated air-leak syndrome (ALS), including pneumothorax and mediastinal/s.c. emphysema, following allogeneic hematopoietic SCT. Eighteen patients (1.2{\%}) developed ALS among 1515 undergoing SCT between 1994 and 2005 at the nine hospitals participating in the Kanto Study Group on Cell Therapy. The median onset of ALS was at 575 days (range: 105-1766) after SCT and 14 patients (77.8{\%}) had experienced late onset noninfectious pulmonary complications (LONIPC) before ALS. Chronic GVHD (cGVHD) was the strongest risk factor for ALS (odds ratio 13.5, P0.013 by multivariate analysis). Repeat SCT, male sex and age 38 years at the time of transplantation were also significant risk factors for ALS. Patients with ALS had a significantly worse survival rate than those without ALS (61.5 vs 14.9{\%} at 3 years; P0.000). The main cause of death was respiratory complications in 8 of the 18 patients. In conclusion, ALS is a rare complication of SCT that is more likely to occur in relatively young male patients with cGVHD and/or LONIPC. It is possible that better understanding and treatment of LONIPC may lead to prevention of ALS.",
keywords = "air-leak syndrome, allo-SCT, chronic GVHD, late onset noninfectious pulmonary complications",
author = "R. Sakai and H. Kanamori and C. Nakaseko and F. Yoshiba and K. Fujimaki and T. Sakura and S. Fujisawa and N. Kawai and M. Onoda and T. Matsushima and A. Maruta and H. Sakamaki and Shinichiro Okamoto",
year = "2011",
month = "3",
doi = "10.1038/bmt.2010.129",
language = "English",
volume = "46",
pages = "379--384",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Air-leak syndrome following allo-SCT in adult patients

T2 - Report from the Kanto Study Group for Cell Therapy in Japan

AU - Sakai, R.

AU - Kanamori, H.

AU - Nakaseko, C.

AU - Yoshiba, F.

AU - Fujimaki, K.

AU - Sakura, T.

AU - Fujisawa, S.

AU - Kawai, N.

AU - Onoda, M.

AU - Matsushima, T.

AU - Maruta, A.

AU - Sakamaki, H.

AU - Okamoto, Shinichiro

PY - 2011/3

Y1 - 2011/3

N2 - We retrospectively investigated air-leak syndrome (ALS), including pneumothorax and mediastinal/s.c. emphysema, following allogeneic hematopoietic SCT. Eighteen patients (1.2%) developed ALS among 1515 undergoing SCT between 1994 and 2005 at the nine hospitals participating in the Kanto Study Group on Cell Therapy. The median onset of ALS was at 575 days (range: 105-1766) after SCT and 14 patients (77.8%) had experienced late onset noninfectious pulmonary complications (LONIPC) before ALS. Chronic GVHD (cGVHD) was the strongest risk factor for ALS (odds ratio 13.5, P0.013 by multivariate analysis). Repeat SCT, male sex and age 38 years at the time of transplantation were also significant risk factors for ALS. Patients with ALS had a significantly worse survival rate than those without ALS (61.5 vs 14.9% at 3 years; P0.000). The main cause of death was respiratory complications in 8 of the 18 patients. In conclusion, ALS is a rare complication of SCT that is more likely to occur in relatively young male patients with cGVHD and/or LONIPC. It is possible that better understanding and treatment of LONIPC may lead to prevention of ALS.

AB - We retrospectively investigated air-leak syndrome (ALS), including pneumothorax and mediastinal/s.c. emphysema, following allogeneic hematopoietic SCT. Eighteen patients (1.2%) developed ALS among 1515 undergoing SCT between 1994 and 2005 at the nine hospitals participating in the Kanto Study Group on Cell Therapy. The median onset of ALS was at 575 days (range: 105-1766) after SCT and 14 patients (77.8%) had experienced late onset noninfectious pulmonary complications (LONIPC) before ALS. Chronic GVHD (cGVHD) was the strongest risk factor for ALS (odds ratio 13.5, P0.013 by multivariate analysis). Repeat SCT, male sex and age 38 years at the time of transplantation were also significant risk factors for ALS. Patients with ALS had a significantly worse survival rate than those without ALS (61.5 vs 14.9% at 3 years; P0.000). The main cause of death was respiratory complications in 8 of the 18 patients. In conclusion, ALS is a rare complication of SCT that is more likely to occur in relatively young male patients with cGVHD and/or LONIPC. It is possible that better understanding and treatment of LONIPC may lead to prevention of ALS.

KW - air-leak syndrome

KW - allo-SCT

KW - chronic GVHD

KW - late onset noninfectious pulmonary complications

UR - http://www.scopus.com/inward/record.url?scp=79952534793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952534793&partnerID=8YFLogxK

U2 - 10.1038/bmt.2010.129

DO - 10.1038/bmt.2010.129

M3 - Article

VL - 46

SP - 379

EP - 384

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -